Intraluminal versus infiltrating gallbladder carcinoma: Clinical presentation, ultrasound and computed tomography

Table 1 Clinical and pathological data from 37 patients with GBCA presented as intraluminal mass, and 28 patients with GBCA presented as infiltrating tumor (mean ± SD) n (%)

	Intraluminal mass	Infiltrating tumor	P value
Age (yr)2	65.49 ± 1.51	73.07 ± 1.90	0.020a
Sex ratio (female)1	23 (62.1)	18 (64.3)	0.861
RUQ or epigastric pain or discomfort1	28 (75.7)	23 (82.1)	0.530
Jaundice1	3 (8.1)	13 (46.4)	< 0.001a
Fever1	3 (8.1)	10 (35.7)	0.006a
Incidental finding	7 (18.9)	3 (8.1)	0.364
Aspartate aminotransferase (IU/L)2	89.36 ± 101.14	74.37 ± 88.62	0.914
Alanine aminotransferase (IU/L)2	113.21 ± 103.97	78.87 ± 82.04	0.252
Alkaline phosphatase (IU/L)2	119.36 ± 87.80	220.68 ± 164.84	0.030a
Total bilirubin (mg/dL)2	1.74 ± 2.87	3.50 ± 3.51	0.011a
Presence of gallstones1	12 (32.4)	22 (78.6)	< 0.001a
Gallbladder size
Length (cm)2	7.47 ± 1.70	6.47 ± 1.83	0.032a
Width (cm)2	4.21 ± 1.43	2.67 ± 0.93	0.026a
T1 tumor1	8 (21.7)	1 (3.6)	0.038a
T2 tumor1	11(29.7)	9 (32.1)	0.835
T3 tumor1	17 (45.9)	16 (57.1)	0.267
T4 tumor1	1 (2.7)	2 (7.2)	0.581
Metastatic lymph nodes1	13 (35.1)	15 (53.6)	0.712
Survival < 12 mo1	16 (43)	18 (68)	0.017a

¹Fisher's exact test or χ² test;

²Wilcoxon rank sum test;

^aSignificant at 0.05; RUQ: Right upper quadrant; GBCA: Gallbladder carcinoma.

Table 2 Comparison of preoperative US and CT diagnosis of 37 patients with GBCA presented as intraluminal mass, and 28 patients with GBCA presented as infiltrating tumor

	Intraluminal mass	Infiltrating tumor
With gallstones	12	22
Preoperative US	11	16
True positive	7	2
False negative	4	14
Sensitivity (%)	63.6	12.5
Preoperative CT	5	14
True positive	4	10
False negative	1	4
Sensitivity (%)	80.0	71.4
Without gallstones	25	6
Preoperative US	23	4
True positive	21	1
False negative	2	3
Sensitivity (%)	91.3	25.0
Preoperative CT	20	4
True positive	20	3
False negative	0	1
Sensitivity (%)	100	75

US: Ultrasound; CT: Computed tomography.